PLA2G4B
Basic information
Region (hg38): 15:41837775-41848147
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the PLA2G4B gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 11 | 20 | ||||
missense | 62 | 10 | 78 | |||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 3 | 4 | 7 | |||
non coding | 0 | |||||
Total | 0 | 0 | 62 | 21 | 15 |
Variants in PLA2G4B
This is a list of pathogenic ClinVar variants found in the PLA2G4B region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
15-41840206-C-G | not specified | Uncertain significance (Feb 23, 2023) | ||
15-41840519-C-T | PLA2G4B-related disorder | Benign (Jun 21, 2019) | ||
15-41840527-C-T | not specified | Uncertain significance (Feb 16, 2023) | ||
15-41840542-A-G | not specified | Uncertain significance (Apr 28, 2022) | ||
15-41840543-C-T | PLA2G4B-related disorder | Likely benign (Apr 10, 2019) | ||
15-41840572-G-A | not specified | Uncertain significance (Jul 20, 2022) | ||
15-41840589-C-T | not specified | Uncertain significance (Feb 13, 2024) | ||
15-41840593-C-T | not specified | Uncertain significance (Jun 22, 2023) | ||
15-41840640-A-G | not specified | Uncertain significance (May 31, 2023) | ||
15-41840775-A-G | not specified | Uncertain significance (Apr 18, 2023) | ||
15-41840781-T-C | not specified | Uncertain significance (Jan 08, 2024) | ||
15-41840837-G-A | not specified | Uncertain significance (Apr 25, 2022) | ||
15-41840858-C-T | JMJD7-PLA2G4B-related disorder | Likely benign (Aug 06, 2019) | ||
15-41840868-G-C | not specified | Uncertain significance (Feb 23, 2023) | ||
15-41840877-G-A | not specified | Uncertain significance (Sep 12, 2023) | ||
15-41840880-G-A | not specified | Likely benign (Sep 13, 2023) | ||
15-41841085-C-T | PLA2G4B-related disorder | Likely benign (Apr 10, 2019) | ||
15-41841242-G-T | not specified | Uncertain significance (Sep 16, 2021) | ||
15-41841252-C-T | Likely benign (Apr 01, 2023) | |||
15-41841253-G-A | not specified | Uncertain significance (Feb 03, 2022) | ||
15-41841258-C-T | JMJD7-PLA2G4B-related disorder | Benign (Oct 17, 2017) | ||
15-41841265-G-A | not specified | Likely benign (Dec 13, 2023) | ||
15-41841521-G-A | not specified | Uncertain significance (Sep 06, 2022) | ||
15-41841538-C-T | not specified | Uncertain significance (Oct 05, 2023) | ||
15-41841540-C-T | PLA2G4B-related disorder | Benign (Nov 25, 2019) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
PLA2G4B | protein_coding | protein_coding | ENST00000542534 | 25 | 20063 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.06e-40 | 3.46e-7 | 125344 | 0 | 404 | 125748 | 0.00161 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -1.99 | 744 | 606 | 1.23 | 0.0000377 | 6479 |
Missense in Polyphen | 242 | 206.03 | 1.1746 | 2291 | ||
Synonymous | -2.79 | 322 | 264 | 1.22 | 0.0000171 | 2069 |
Loss of Function | -0.453 | 59 | 55.4 | 1.07 | 0.00000246 | 613 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00650 | 0.00628 |
Ashkenazi Jewish | 0.000306 | 0.000298 |
East Asian | 0.00238 | 0.00234 |
Finnish | 0.0000925 | 0.0000924 |
European (Non-Finnish) | 0.00101 | 0.000985 |
Middle Eastern | 0.00238 | 0.00234 |
South Asian | 0.00335 | 0.00334 |
Other | 0.00148 | 0.00147 |
dbNSFP
Source:
- Function
- FUNCTION: Calcium-dependent phospholipase A2 that selectively hydrolyzes glycerophospholipids in the sn-2 position with a preference for arachidonoyl phospholipids. Has a much weaker activity than PLA2G4A. Isoform 3 has calcium-dependent activity against palmitoyl-arachidonyl-phosphatidylethanolamine and low level lysophospholipase activity but no activity against phosphatidylcholine. Isoform 5 does have activity against phosphatidylcholine. {ECO:0000269|PubMed:10085124, ECO:0000269|PubMed:10358058, ECO:0000269|PubMed:16617059}.;
- Pathway
- Inflammatory mediator regulation of TRP channels - Homo sapiens (human);Platelet activation - Homo sapiens (human);Oxytocin signaling pathway - Homo sapiens (human);Fc epsilon RI signaling pathway - Homo sapiens (human);Fc gamma R-mediated phagocytosis - Homo sapiens (human);Ether lipid metabolism - Homo sapiens (human);VEGF signaling pathway - Homo sapiens (human);Glycerophospholipid metabolism - Homo sapiens (human);Choline metabolism in cancer - Homo sapiens (human);Serotonergic synapse - Homo sapiens (human);Glutamatergic synapse - Homo sapiens (human);Long-term depression - Homo sapiens (human);GnRH signaling pathway - Homo sapiens (human);Necroptosis - Homo sapiens (human);Vascular smooth muscle contraction - Homo sapiens (human);alpha-Linolenic acid metabolism - Homo sapiens (human);Arachidonic acid metabolism - Homo sapiens (human);Linoleic acid metabolism - Homo sapiens (human);Ras signaling pathway - Homo sapiens (human);MAPK signaling pathway - Homo sapiens (human);Phospholipase D signaling pathway - Homo sapiens (human);Ovarian steroidogenesis - Homo sapiens (human);Platelet Aggregation Inhibitor Pathway, Pharmacodynamics;Etodolac Action Pathway;Ketoprofen Action Pathway;Ibuprofen Action Pathway;Rofecoxib Action Pathway;Acetylsalicylic Acid Action Pathway;Diflunisal Action Pathway;Leukotriene C4 Synthesis Deficiency;Acetaminophen Action Pathway;Celecoxib Action Pathway;Sulindac Action Pathway;Diclofenac Action Pathway;Ketorolac Action Pathway;Naproxen Action Pathway;Etoricoxib Action Pathway;Carprofen Action Pathway;Flurbiprofen Action Pathway;Fenoprofen Action Pathway;Antrafenine Action Pathway;Antipyrine Action Pathway;Lumiracoxib Action Pathway;Magnesium salicylate Action Pathway;Alpha Linolenic Acid and Linoleic Acid Metabolism;Trisalicylate-choline Action Pathway;Nepafenac Action Pathway;Phenylbutazone Action Pathway;Lornoxicam Action Pathway;Salsalate Action Pathway;Tenoxicam Action Pathway;Tiaprofenic Acid Action Pathway;Tolmetin Action Pathway;Salicylic Acid Action Pathway;Salicylate-sodium Action Pathway;Oxaprozin Action Pathway;Valdecoxib Action Pathway;Nabumetone Action Pathway;Phospholipid Biosynthesis;Indomethacin Action Pathway;Meloxicam Action Pathway;Suprofen Action Pathway;Bromfenac Action Pathway;Mefenamic Acid Action Pathway;Arachidonic Acid Metabolism;Piroxicam Action Pathway;XBP1(S) activates chaperone genes;MAPK Signaling Pathway;Ras Signaling;Acyl chain remodelling of PG;Metabolism of lipids;Metabolism;phospholipases;Acyl chain remodelling of PC;Linoleate metabolism;Glycerophospholipid metabolism;Acyl chain remodelling of PS;Glycerophospholipid biosynthesis;Phospholipid metabolism;Hydrolysis of LPC;Acyl chain remodelling of PE;Synthesis of PA;Arachidonic acid metabolism
(Consensus)
Recessive Scores
- pRec
- 0.103
Intolerance Scores
- loftool
- rvis_EVS
- 0.06
- rvis_percentile_EVS
- 58.01
Haploinsufficiency Scores
- pHI
- 0.179
- hipred
- N
- hipred_score
- 0.146
- ghis
- 0.533
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.114
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Pla2g4b
- Phenotype
Gene ontology
- Biological process
- phospholipid metabolic process;phosphatidic acid biosynthetic process;inflammatory response;parturition;arachidonic acid metabolic process;calcium-mediated signaling;phosphatidylglycerol acyl-chain remodeling;phosphatidylserine acyl-chain remodeling;phosphatidylcholine acyl-chain remodeling;phosphatidylethanolamine acyl-chain remodeling;IRE1-mediated unfolded protein response;glycerophospholipid catabolic process
- Cellular component
- extracellular region;cytoplasm;mitochondrial inner membrane;cytosol;early endosome membrane
- Molecular function
- lysophospholipase activity;phospholipase A2 activity;calcium ion binding;calcium-dependent phospholipid binding;phospholipase A1 activity;calcium-dependent phospholipase A2 activity;phospholipase A2 activity (consuming 1,2-dipalmitoylphosphatidylcholine);phospholipase A2 activity consuming 1,2-dioleoylphosphatidylethanolamine)